Results 71 to 80 of about 145,743 (338)

Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?

Liječnički vjesnik, 2023
Breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2) is considered to be HER2-positive. The novel HER2- directed antibody drug conjugate, trastuzumab deruxtecan (T-DXd), is formed by covalently joining the monoclonal ...
Džana Bjelić, Sara Bognar, Jelena Benčić, Manuela Bajan, Natalija Dedić Plavetić   +4 more
doaj   +1 more source

Biological properties of adriamycin bound to biodegradable polymeric carriers [PDF]

, 1993
Three different conjugates having adriamycin (ADR) bound to the side chain carboxyl groups of high-molecular weight poly (¿--glutamic acid) (PGA) either directly or by interpolation of GlyGly and GlyGlyGlyLeu spacers, respectively, were compared with ...
Bhakoo, M., Bouma, J.M.W., Duncan, R., Feijen, Jan, Grootoonk, J., Grootoonk, J., Hoes, C.J.T., Hoes, C.J.T., Hume, I.C.   +8 more
core   +3 more sources

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations

Biomolecules, 2020
The ability of monoclonal antibodies to specifically bind a target antigen and neutralize or stimulate its activity is the basis for the rapid growth and development of the therapeutic antibody field.
Hyunbo Shim
doaj   +1 more source

Progresses in research and development of antibody-drug conjugate

生物医学转化, 2021
Through referring to the literature and related databases, the research process of antibodyconjugated drugs was reviewed, and the key elements of ADC were summarized.
Wu Gang, Fu Zhihao, Xu Gangling, Wang Wenbo, Yu Chuanfei, Wang Lan, Wang Junzhi   +6 more
doaj   +1 more source

The Dawn of the Antibody–Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors [PDF]

, 2022
Paolo Tarantino, Sara M. Tolaney
openalex   +1 more source

Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves [PDF]

, 2015
peer-reviewedBackground There is a need to improve vaccination against respiratory pathogens in calves by stimulation of local immunity at the site of pathogen entry at an early stage in life. Ideally such a vaccine preparation would not be inhibited by
A Menanteau-Horta, A Vila, AR Peters, B Morein, B Morein, Bernadette Earley, BJF Bradshaw, BM Adair, Bryan Markey, C Pilette, CA Siegrist, CX Song, DG Bryson, DP Greenberg, EM Liebler-Tenorio, F Alexis, F Mansoor, Fawad Mansoor, FM Buonaguro, HM Chen, I Vangeel, J Phillips, J Pollock, JE Crowe, Joseph P. Cassidy, JS Salt, K Tahara, KJ Wiechelman, M Garinot, M Higaki, Michael D. Welsh, ML Hans, MS Lee, OV Kavanagh, PE Shewen, PK Smith, PR Wood, RE Brown, RM Zinkernagel, S Lofthouse, Simon Doherty, TG Kimman, YJ Kwon   +42 more
core   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

Extracellular vesicles as modifiers of antibody‐drug conjugate efficacy

Journal of Extracellular Vesicles, 2021
Antibody‐drug conjugates (ADCs) are a new class of anti‐cancer drugs that consist of a monoclonal antibody, a highly potent small‐molecule cytotoxic drug, and a chemical linker between the two. ADCs can selectively deliver cytotoxic drugs to cancer cells
Mark Barok, Maija Puhka, Narjes Yazdi, Heikki Joensuu   +3 more
doaj   +1 more source

PR062/#686  First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer [PDF]

, 2023
Gottfried E. Konecny, Andrea Wahner Hendrickson, Boris Winterhoff, Cinthiya Chander, Sanela Bilic, Simon Davenport, Adrine Chung, L.L. Miller, Michael F. Press, Stephen P. Letrent, Dennis J. Slamon   +10 more
openalex   +1 more source